Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00151736 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00151736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00151736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2004
Completion date
February 29, 2008
Enrollment
88 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia